Zenosense Inc. (ZENO) – an Emerging Growth Company

Zenosense Inc. is the holder of an exclusive global license agreement to develop and market effective medical devices for use in hospitals and primary healthcare settings targeting the early detection of both deadly bacteria and certain cancers in the exhaled breath of patients. Two devices are currently under development; a device intended to detect the Methicillin-resistant Staphylococcus aureus “Super-Bug” (MRSA); and a device intended to detect Lung Cancer. Using a common Electronic Nose technology platform, the devices analyze Volatile Organic Compounds (VOCs) which are present in the exhaled breath of patients, scanning for certain biomarkers which can indicate the presence of infection/illness.


Zenosense Inc. – Early detection saves lives! (ZENO)

It’s been all over the TV. Masked health workers screening airplane passengers for elevated body temperatures that can signal Ebola infection.

They’re screening with a simple “temperature gun.” It’s not fool-proof by a long shot. But it’s all that’s currently available. Even this elementary screening could potentially save millions of lives by early detection and preventing an Ebola-infected traveler triggering a world-wide pandemic.

Hopefully, Ebola will be contained. And while each of its victims is a tragic loss, the highly-publicized Ebola outbreak has drawn the world’s attention to the life-or-death importance of early and reliable detection of all deadly diseases.